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Abstract
Background: Prostate cancer shows an extremely slow progression, appearing in its metastatic, hormone refractory 
phenotype mostly in elderly men. The chemopreventive targeting of this tumor could accordingly delay its 
malignancy over life expectancy. The cancer chemopreventive retinoid N-(4 hydroxyphenyl)retinamide (4HPR) has 
already been shown to restrain prostate cancer growth in vitro and in vivo, though its mechanisms of action are only 
partially explained.
Results: We found that 4HPR impairs DU145 and PC3 prostate cancer cells migration and invasion by down-regulating 
FAK and AKT activation and by enhancing β-catenin degradation, causing the downregulation of target genes like 
cyclin D1, survivin and VEGF. This non-migratory phenotype was similarly produced in both cell lines by stable silencing 
of β-catenin. 4HPR was able to decrease AKT phosphorylation also when powerfully upregulated by IGF-1 and, 
consequently, to impair IGF-1-stimulated cell motility. Conversely, the expression of constitutively active AKT (myr-AKT) 
overcame the effects of 4HPR and β-catenin-silencing on cell migration. In addition, we found that BMP-2, a 4HPR 
target with antiangiogenic activity, decreased prostate cancer cell proliferation, migration and invasion by down-
regulating the pathway described involving AKT phosphorylation, β-catenin stability and cyclin D1 expression.
Conclusion: These data point to 4HPR as a negative regulator of AKT phosphorylation, effectively targeting the β-
catenin pathway and inducing a relatively benign phenotype in prostate cancer cells, limiting neoangiogenesis and 
cell invasion.
Background
Prostate cancer (PC) is the most frequent cancer in men
of western countries. About 1 man in 5 is diagnosed with
PC during his lifetime and 1 man in 33 will die of this dis-
ease. As the population age is increasing, these numbers
are expected to increase. PC cells usually remain confined
in the organ, while a small proportion of carcinomas
acquire the ability to metastasize and approximately 80%
of patients who have died of advanced hormone refrac-
tory PC have clinical evidence of bone metastasis. Early
stage disease differs from later stages in tumor volume,
localization and metastatic potential. Processes involved
in later stage disease, like development of androgen inde-
pendence as a consequence of androgen depletion ther-
apy, neoangiogenesis and homing of metastatic cells in
lymphatic or bone tissues are generally undetectable at
early stages. Among control strategies, chemoprevention
attempts in preclinical studies to halt or delay these pro-
cesses are now proving the potential efficacy of this
approach.
4HPR, also known as fenretinide, has received great
attention as a chemopreventive agent based on the cumu-
lative results of numerous in vitro and animal studies, as
well as chemoprevention clinical trials [1]. 4HPR admin-
istration prevents prostate tumor growth and metastasis
in animals [2-6] and functions as an apoptosis inducer in
human prostate cancer cells in vitro [7-9] mostly through
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the production of reactive oxygen species (ROS) and
mitochondrial disruption [1]. Interestingly, 4HPR was
shown to lower circulating insulin-like growth factor I
(IGF-I) levels which have been associated with a higher
risk of prostate cancer in several cohort studies [10,11].
W e  a n d  o t h e r s  h a v e  p r e v i o u s l y  r e p o r t e d  t h a t  t h e
chemopreventive effects of 4HPR in early intervention
protocols are likely due to its antiangiogenic properties
[4,12-16]. Since angiogenesis and metastatic spread are
strictly related, in this study we analyzed the regulation of
multiple signaling pathways responsible for cancer cell
invasion. We found that 4HPR-induced inhibition of PC
cell migration and invasion correlates with decreased
FAK and AKT phosphorylation, activation of the glyco-
gen synthase kinase 3β(GSK3β) and β-catenin destabili-
zation. As a consequence, 4HPR led to the regulation of
genes controlling cell proliferation, angiogenesis and
metastasis. For the slow evolving prostate tumor to
become metastatic multiple mechanisms must be acti-
vated and our results identify novel points of regulation
by 4HPR, independent of ROS generation, that further
support its use as a chemopreventive or therapeutic
agent. Due to its pleiotropic activities, 4HPR could be
used alone, with other chemopreventive molecules exhib-
iting complementary mechanisms of action, or in combi-
nation with chemotherapy to treat prostate cancer.
Methods
Cell culture and reagents
Androgen-independent DU145 and PC3 prostate carci-
noma cell lines (ATCC, Rockville, MD) were cultured in
RPMI containing 10% heat-inactivated FCS. DU145 sub-
clones resistant to 5 μM 4HPR (R5) were established from
cultures progressively exposed to increasing concentra-
tions of 4HPR starting from 1 μM and cloning by limiting
dilution following published procedures [17]. 4HPR
(kindly provided by Dr. James A. Crowell, Division of
Cancer Prevention, NCI, Bethesda and Dr. Gregg Bullard,
McKessonBio, Rockville, MD) was dissolved in ethanol at
a stock concentration of 10 mM and stored in aliquots at -
20°. Wortmannin, LY294002, N-Acetyl-L-cysteine (NAC)
and diphenyleneiodionium chloride (DPI) were from
Sigma (Milano, Italy), IGF-1 and bone morphogenetic
protein-2 (BMP-2) were from R&D (Minneapolis, MN,
USA). VEGF protein released into the media by PC cells
was measured using a commercial human ELISA kit (Bio-
source, Invitrogen, Carlsbad, CA, USA).
Cell proliferation, apoptosis, chemotaxis and invasion 
assays
In vitro cell proliferation was performed on cells plated in
96-well plates at 3,000 cells/well dilution and grown in
complete medium or treated as described. The medium
was changed every two days. At different time points, the
number of viable cells was evaluated by the crystal violet
assay.
Chemotaxis and chemoinvasion assays were carried out
in Boyden chambers as previously described [18]. The
cells (12 × 104/chamber) were extensively washed with
PBS, resuspended in serum-free media (SFM) and placed
in the upper compartment with or without selected mole-
cules. In parallel experiments, trypan blue exclusion
under all the conditions tested showed no altered cell
proliferation or viability compared with controls during
the five hours of chemotaxis test. The two compartments
of the Boyden chamber were separated by 8 μm pore-size
polycarbonate filters coated with 5 μg/50 μl/filter of colla-
gen type IV (diluted in H2O, 0.1% CH3COOH) for the
chemotaxis assay, or with Matrigel (60 μg/filter), a recon-
stituted basement membrane, for the invasion assay.
Serum free 24 h-conditioned medium from human fibro-
blasts (FB-CM) was used as a chemoattractant in the
lower chamber. After 5 hours of incubation at 37° in 5%
CO2, the filters were recovered, fixed in ETOH and
stained by Toluidine blue after removal of the non-
migrating cells on the upper surface. The migrated cells
were quantified counting five to ten fields for each filter
under a microscope. Graphical results are shown as per-
cent inhibition as compared to a 100% untreated control.
Protein extraction and western blot analyses
Proteins were obtained from PC cells after four hours cul-
ture in the absence or presence of the indicated molecules
as described in the text and in figure legends, or after 4
days in the presence of BMP-2 (50-100 ng/ml). To per-
form AKT activation, thirty min before the end of the
incubation, the cells were stimulated with IGF-I (100 ng/
ml). The cells were then lysed in RIPA buffer containing
protease inhibitors. Protein concentration was deter-
mined with the DC Protein Assay kit (Bio-Rad). Equal
amounts of samples were resolved by SDS-PAGE, trans-
ferred to nitrocellulose and probed at 4°C overnight with
the following anti-human antibodies (Cell Signaling
Technology, Beverly, MA): rabbit polyclonal anti-phos-
pho-FAK (Tyr576/577), phospho-AKT-1 (Ser473), phos-
pho-GSK3β (Ser9), β-catenin, phospho-β-catenin
(Ser552), cyclin D1, survivin and E-cadherin. After wash-
ing, the blots were incubated for 1 h at room temperature
with horseradish peroxidase-conjugated secondary anti-
bodies (GE-Healthcare, Milano, Italy) and specific com-
plexes were revealed by enhanced chemiluminescence
(ECL, GE-Healthcare). An anti-GAPDH antibody conju-
gated to horseradish peroxidase (Novus Biologicals, Lit-
tleton, CO) or a mouse monoclonal anti-β-tubulin
antibody (Sigma, Milano, Italy) were utilized as loading
controls for all samples.Benelli et al. Molecular Cancer 2010, 9:142
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Plasmid DNA, RNA silencing and transfections
pCMV6-Myr.Akt (a constitutively active Akt) and control
vector were kindly provided by Dr. Alex Toker of the Beth
Israel Deaconess Medical Center of Boston. Transient
transfections were performed with lipofectamine 2000
(Invitrogen). β-catenin was silenced using a lentiviral vec-
tor expressing short hairpin RNA (MISSION shRNA
clones, Sigma) following manufacturer's instructions.
This resulted in the generation of stable DU145 and PC3
cells showing decreased β-catenin expression. Control
vectors contained scrambled sequences.
Statistical analysis
Data are expressed as means ± SD. The statistical signifi-
cance between two data sets was determined by two-
tailed unpaired Student's t test using the PRISM Graph-
Pad software.
Results
4HPR decreases cell proliferation, migration and invasion
We first assessed the action of 4HPR on prostate cancer
cell proliferation by treating DU145 and PC3 cells with a
range of concentrations. All the concentrations tested
inhibited cell growth, with statistically significant differ-
ences only after 96 h exposure (Fig 1A, B left panels).
Migration of cancer cells is one of the key factors
responsible for cancer metastasis. To metastasize, cancer
cells must migrate from the original growth site, invade
surrounding tissues and locate to other parts of the body
through the blood or the lymphatic system. The effects of
4HPR on PC cell migration and invasion were then tested
in a broad dose/response experiment. Untreated PC cells
migrated (Fig. 1A, B middle; DU145 and PC3 respec-
tively) and invaded through Matrigel (Fig. 1A, B right;
DU145 and PC3 respectively) in response to fibroblast
conditioned medium (FB-CM). A very short exposure (5
h) to micromolar concentrations of 4HPR significantly
inhibited migration and invasion of DU145 (Fig. 1A) and
PC3 (Fig. 1B) cells. To explore the possibility that ROS
induction by 4HPR was a mechanism underlying these
effects, PC3 cells were pretreated 1 h with the ROS scav-
engers NAC and DPI (at 10 mM and 1 μM respectively)
and then subjected to chemotaxis in the presence of
4HPR at different concentrations. As shown in Fig. 1C,
both compounds did not modify 4HPR effects. Addi-
tional Fig. 1 (Fig. 1S) shows that 30 min pretreatment
with the ROS scavenger N-Acetyl Cysteine (NAC) at 10
mM significantly decreases ROS production induced by
4HPR treatment (1 h at 5 μM).
4HPR modulates biological responses involved in the 
metastatic process of prostate cancer
Focal adhesion kinase (FAK) is a non-receptor tyrosine
kinase that plays an important role in signal transduction
and is a key regulator of survival, proliferation, migration
and invasion. Overexpression and/or increased activity of
FAK are common in a wide variety of human cancers,
implicating a role for FAK in carcinogenesis. DU145 and
PC3 cells express high levels of activated FAK, which was
rapidly (4 hours) downregulated by 4HPR (Fig. 2A, B).
The survival and migratory signaling mediated by FAK
operates via activation of the PI3K/AKT pathway [19,20]
that in turn promotes prostate cancer cell migration and
invasion [21]. Exposure to 4HPR rapidly decreased AKT
phosphorylation in both cell lines (Fig. 2A, B). In agree-
ment, prostate cancer cell migration towards FB-CM was
significantly inhibited in the presence of the specific PI3K
inhibitors Wortmannin (Wort, 200 nM) and LY294002
(LY, 10 μM). Co-exposure of the inhibitors with 4HPR
produced more pronounced effects being the combina-
tion Wotmannin/4HPR the most effective. (Fig. 2C,
DU145 cells; PC3 cells gave similar results). These data
suggest that these pathways are partially independent of
each other. As AKT overexpression correlates with
increased VEGF levels and prostate tumor angiogenesis
[22], we determined VEGF release in 4HPR-treated cells
by ELISA. We noted that 4HPR-induced AKT downregu-
lation is associated with reduced VEGF secretion (Fig.
2D).
The AKT activator IGF-1 is a potent mitogenic and
motogenic factor and has a prominent role in protection
against apoptosis and cell survival. IGF-1 has been impli-
cated in the initiation and progression of several different
cancers including prostate cancer [23]. Chemotaxis
assays showed that IGF-1 stimulates androgen-indepen-
dent DU145 prostate cancer cell migration and co-expo-
sure to 4HPR completely abrogated the effect (Fig. 3A).
Accordingly, activation of the AKT signaling pathway by
a short exposure to IGF-I (30 min at 100 ng/ml), as
detected by western blot analysis, was lowered by 4HPR
pretreatment (Fig. 3B).
Next, we determined the effect of overexpression of
myristoylated Akt (Myr.Akt), which is anchored to the
plasma membrane and has a constitutively active kinase
activity. Cells transfected with the empty vector were
used as controls. Western blot analysis of extracts from
DU145 cells transiently transfected with constitutively
active Akt showed high levels of total Akt and phospho-
rylated (Ser 473)-Akt as compared with the empty vector-
transfected control cells (Fig. 3C). Ectopic expression of
constitutively active Akt abrogated 4HPR-mediated inhi-
bition of DU145 cell migration (Fig. 3C).
The oncogenic hub β-catenin is a molecular target of 4HPR
β-catenin is a multifunctional protein not only involved
structurally in the adherens junction complex, but also
acting as a signaling molecule promoting cancer cell pro-
liferation, survival and migration. β-catenin signaling isBenelli et al. Molecular Cancer 2010, 9:142
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Figure 1 Inhibition of androgen-independent DU145 (A) and PC3 (B) prostate cancer cell growth, migration and invasion by increasing 
doses of 4HPR is independent of ROS production (C). Cell proliferation, evaluated by the crystal violet assay, is significantly inhibited at all 4HPR 
concentrations tested after 96 h exposure (***P < 0.001). In migration and invasion assays, the conditioned medium from human fibroblasts (FB-CM) 
was used as chemoattractant in the lower chamber. Experiments were done in triplicate and repeated thrice. Means ± SD are shown (*P < 0.05, **P < 
0.01, ***P < 0.001).Benelli et al. Molecular Cancer 2010, 9:142
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Figure 2 4HPR inhibits FAK and AKT activity in prostate cancer cells, thus controlling their migratory potential and VEGF release. Western 
blot analyses show a remarkable decrease of FAK and AKT phosphorylation after 4 h of treatment with 4HPR in DU145 (A) and PC3 (B) cells. C). The 
specific PI3K/AKT inhibitors Wortmannin (Wort, 200 nM) and LY294002 (LY, 10 μM) significantly impair the chemotaxis of DU145 cells towards FB-CM 
similar to 4HPR (5 μM). Co-treatment with Wortmannin and 4HPR produces an even more pronounced effect. Similar results were obtained with PC3 
cells. Experiments were done in triplicate and repeated thrice. Comparisons were made with control cells. Means ± SD are shown (***P < 0.001). D). 
Decreased AKT activity induced by 4HPR correlates with reduced VEGF secretion by DU145 and PC3 exposed for 16 h to the drug and analyzed by 
ELISA. Means ± SD are shown (*P < 0.05, **P < 0.01, ***P < 0.001).Benelli et al. Molecular Cancer 2010, 9:142
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Figure 3 4HPR antagonizes AKT activation by IGF-I but not constitutively active AKT. A). DU145 cell migration towards FB-CM is significantly 
enhanced by IGF-I (100 ng/ml), as compared to control cells. IGF-I effects are completely abrogated when cell migration is carried out in the presence 
of 4HPR (5 μM). Experiments were done in triplicate and repeated thrice. Means ± SD are shown (*P < 0.05, ***P < 0.001). B). Western blot analysis of 
extracts from DU145 cells pulsed for 30 min with IGF-I at 100 ng/ml show strong AKT phosphorylation, almost completely abolished by 4 h pretreat-
ment with 5 μM 4HPR. C). DU145 cells transiently transfected with a constitutively active form of AKT (Myr.Akt) and showing high levels of pAKT as 
compared to vector transfected control cells (inset) are no more susceptible to 4HPR-induced inhibition of cell migration. PC3 transfected cells pro-
duced similar results.Benelli et al. Molecular Cancer 2010, 9:142
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aberrantly activated in greater than 70% of colorectal can-
cers and has been shown to play a causative role in pros-
tate cancer [24]. As β-catenin turnover is triggered by
GSK-3β, a well known target of AKT, we made β-catenin
signaling a focal point of our investigation. We measured
the soluble levels of β-catenin by western blot analysis in
4HPR-treated DU145 cells (Fig. 4A, left) and evaluated
cyclin D1 and survivin as typical transcriptional targets of
the β-catenin/TCF/LEF complex [25,26] (Fig. 4A, mid-
dle). As shown in Figure 4A, DU145 cells exhibited high
levels of β-catenin, cyclin D1 and survivin expression. A
short exposure to 4HPR (4 hours) resulted in a significant
reduction in the levels of these proteins. Pre-incubation
of cells with the ROS scavenger NAC (1 h at 10 mM) did
not compromise the ability of 4HPR to modulate β-
catenin thus suggesting a redox-independent signaling
(Fig. 4A right). Similar results were obtained with PC3
cells (data not shown). These data suggest that the highly
activated β-catenin signaling was suppressed by short-
term 4HPR treatment in prostate tumor cells.
The expression of β-catenin is rather low in non-cancer
cells as GSK-3β causes its phosphorylation and conse-
quent degradation by the ubiquitin-proteasome pathway.
GSK-3β activity is suppressed when it is phosphorylated
on serine 9 by AKT. In agreement with the decreased
phosphorylation of AKT after 4HPR treatment (Fig. 2A,
B, 3B), GSK-3β phosphorylation was decreased by 4HPR
(Fig. 4A, left). As a confirmation, a short exposure (2 hrs)
to the specific PI3K/AKT inhibitors Wortmannin and
LY294002 reduced GSK3β phosphorylation,β-catenin
and cyclin D1 levels (Fig. 4B). AKT was also shown to
directly phosphorylate β-catenin at Ser552, independent
of GSK3β. Phosphorylation at Ser552 induces β-catenin
accumulation in the nucleus, increases its transcriptional
activity and promotes cell invasion [27,28]. According to
AKT inhibition by 4HPR exposure, β-catenin phosphory-
lated at Ser552, probably representing the residual
nuclear pool escaping proteasomal degradation, was
decreased (Fig. 4A, left). Activation of AKT by IGF-I
exposure (Fig. 4C) suppressed GSK3β activity, stabilized
β-catenin, increased Ser552 phosphorylation and cyclin
D1 levels, yet pretreatment with 4HPR abolished the
effects of IGF-I stimulation (Fig. 4C). Together, all these
data suggest that 4HPR-induced pAKT down-regulation
exerts a multi-level control on total and nuclear β-
catenin, dependent and independent of GSK3β activity.
Figure 4 4HPR regulates the β-catenin soluble pool, its transcriptionally active phosphorylated (Ser522) form, GSK3β phosphorylation, cy-
clin D1 and survivin expression. A). Dose-dependent decrease of β-catenin and phospho-β-catenin (Ser522), and GSK3β- phosphorylation after 4 
h of treatment in DU145 cells (left) is associated with reduced levels of the proliferation/survival related genes cyclin D1 and survivin (middle). Loss of 
β-catenin stability is independent of ROS production as demonstrated by incubating the cells in the presence of the ROS scavenger NAC (right). B). 
Similar to 4HPR, 4 hours incubation with the specific PI3K/AKT inhibitors wortmannin (Wort, 200 nM) and LY294002 (LY, 10 μM) activate GSK3β and 
reduce the soluble pool of β-catenin and cyclin D1 levels. C). IGF-I (4 hours at 100 ng/ml), through AKT activation, causes inhibition of its down-stream 
effector GSK3β, thus leading to β-catenin stabilization, β-catenin (ser522) phosphorylation and cyclin D1 accumulation. 4HPR (5 μM) co-exposure can 
still antagonize IGF I-induced AKT activity and reduce β-catenin and cyclin D1 levels. The experiments were repeated thrice and similar results were 
obtained with PC3 cells.Benelli et al. Molecular Cancer 2010, 9:142
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In order to understand whether the observed signaling
was univocally related to sensitivity of cell lines to 4HPR,
our analysis was extended to DU145/R5, a cell line resis-
tant to 5 μM 4HPR generated by in vitro incubation of
DU145 cells with increasing concentrations of 4HPR.
Supplementary Fig. 2 (Fig. 2S) shows that DU145/R5 cells
grow (96 h treatment, panel A) and migrate (5 h treat-
ment, panel B) in the presence of 2.5 and 5 μM 4HPR.
This 4HPR-resistant phenotype is associated to very high
levels of phosphorylated AKT (panel C).
Effect of β-catenin silencing in human prostate cancer 
DU145 and PC3 cells
We first investigated whether specifically reducing the
levels of β-catenin resulted in decreased proliferation,
migration and invasiveness. For this analysis, RNA inter-
ference with shRNAs directed against β-catenin (sh-βcat)
was used and comparisons were made with controls with
scrambled sequences (sh-NT). As shown in Fig. 5,
shRNA targeting of β-catenin (insets panel A) resulted in
a 40% and 30% decrease in cell proliferation seen at 96 h
(Fig. 5A, DU145 and PC3 cells respectively). β-catenin
silencing significantly reduced also cell migration (Fig.
5B, DU145 and PC3 cells respectively) and invasiveness
(Fig. 5C, DU145 and PC3 cells respectively).
Next, we determined whether constitutively active Akt
(Myr.Akt) could abrogate the effects of β-catenin silenc-
ing on cell migration and invasion. β-catenin-silenced
DU145 cells transiently expressing Myr.Akt showed an
enhanced migratory and invasive phenotype as compared
to control vector transfected cells (Fig. 5D). In these cells
GSK3β phosphorylation and β-catenin levels remained
unaltered (Fig. 5D, right panel), as previously reported
[29], suggesting that under these conditions activation of
Akt alone is not able to restore β-catenin levels through
increased expression or stabilization.
4HPR-induced BMP2 in an anti-angiogenic setting 
antagonizes prostate cancer cell growth and invasiveness
Metastasis and angiogenesis are strictly related processes.
We reported that the TGF-β family member BMP-2 is a
mediator of the antiangiogenic activity of 4HPR [14],
controlling tumor growth. Since the role of BMPs in the
formation of prostate cancer metastases remains
unknown and controversial, we tested whether BMP-2
could influence PC cell growth, migration and invasion.
We previously found [14] that the exposure of endothelial
HUVE cells to 5 μM 4HPR caused the release of BMP-2
in the culture medium (50-100 ng/ml concentrations).
When DU145 and PC3 cells were exposed to the same
BMP-2 concentrations in long-term experiments (4 days
and in the absence of 4HPR), cell growth, migration and
invasion were significantly decreased in both cell lines
(Fig. 6A, B). BMP signaling downregulates the β-catenin
pathway in cancer cells [30,31]. While negative regulation
on the β-catenin pathway by BMP signaling has been rec-
ognized to have a role in intestinal tumorigenesis in mice
and humans [30,31] information is lacking about the rela-
tionships between the two pathways in prostate tumors.
Western blot analysis of nuclear extracts from PC3 cells
exposed for 4 days to BMP-2 (50-100 ng/ml) showed a
dose-dependent decrease of nuclear β-catenin (Fig. 6C).
We then looked at the possible mechanisms controlling
β-catenin accumulation. We found that BMP-2 modu-
lates AKT phosphorylation (Fig. 6C), but not that of
pGSK3β (data not shown), further confirming that in
prostate cancer cells β-catenin nuclear signaling is mainly
controlled by AKT activity. As β-catenin promotes tran-
scription of the proliferation gene cyclin D1, we also
noted that BMP-2-treated cells exhibited significantly
lower levels of cyclin D1 (Fig. 6D).
E-cadherin enforces cell-cell contacts forming the
adherens junctions and is anchored to actin filaments by
β and α catenin. E-cadherin loss promotes metastasis by
enabling the first step of the metastatic cascade: the dis-
aggregation of cancer cells from each another. BMP-7,
another member of the BMP family, has been reported to
be a potent inhibitor of prostate cancer metastasis [32]
also acting through E-cadherin induction. PC3 cells
exposed to BMP-2 exhibited increased levels of E-cad-
herin (Fig. 6D) suggesting that BMP-7 and BMP-2 have
similar mechanisms of action. We cannot exclude, how-
ever, that β-catenin downregulation controls E-cadherin
expression as reported for other compounds [33].
Discussion
Prostate cancer is the most frequently diagnosed cancer
in men and a leading cause of cancer death. Although the
5-year survival rate is excellent for localized stages, the
survival dramatically decreases when prostate cancer
metastasizes. Decades of research have revealed that can-
cer is easier to prevent than to treat and for individuals at
a high risk of developing cancer and/or for slow evolving
cancers, such as prostate cancer, chemoprevention is a
logical approach. Preneoplastic lesions such as high-
grade prostatic intraepithelial neoplasia (PIN) are fre-
quently observed in asymptomatic young men and it is
believed that such lesions require two to three decades to
develop into clinically relevant prostate cancer. The fact
that prostate cancer is associated with advanced age again
suggests that chemopreventive agents inhibiting or delay-
ing the onset of malignancy might be recommended.
Identification of molecular targets and signaling path-
ways of chemoprevention are therefore relevant to cancer
therapy.
Several studies have reported a remarkable preventive
activity of 4HPR in animal models of prostate cancer [2-
6], but pilot clinical trials gave less encouraging results.Benelli et al. Molecular Cancer 2010, 9:142
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Figure 5 β-catenin levels control prostate cancer cell proliferation, migration and invasiveness. A). DU145 and PC3 cells permanently trans-
fected with β-catenin shRNA sequences (Sh- βcat) had decreased levels of β-catenin as compared to non-target shRNA control vector (sh-NT) trans-
fected cells (insets) and showed decreased cell proliferation as evaluated by the crystal violet assay. β-catenin silenced DU145 and PC3 cells had 
impaired ability to migrate toward FB-conditioned medium (B) and to invade through matrigel (C). D). Sh- βcat DU145 cells were transiently cotrans-
fected with activated AKT (Myr.Akt) or empty vector (vector) and 24 hours after transfection assayed for their ability to migrate toward FB-conditioned 
medium or to invade through matrigel. Although AKT activation greatly nullify the effects of β-catenin silencing on cell migration and invasion, acti-
vation of Akt alone was not able to phosphorylate and inhibit the GSK3β pool involved in β-catenin up-regulation, thus β-catenin levels remained 
unaltered (right panel). All results are representative of three independent experiments (***P < 0.001).Benelli et al. Molecular Cancer 2010, 9:142
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Figure 6 Effects of 4 days administration of BMP-2 (50-100 ng/ml) on growth, migration, invasion and transcriptional activity of DU145 and 
PC3 cells. Cell growth, as evaluated by the crystal violet assay, is significantly inhibited by BMP-2 at 48 and 96 h (A, B, left panels, DU145 and PC3 cells 
respectively). Means ± SD of three independent experiments run in sextuplicate are shown (*P < 0.05, **P < 0.01, ***P < 0.001). DU145 and PC3 cells 
exposed for 4 days to 50-100 ng/ml BMP-2 and then subjected to the chemotaxis assay show a decreased migratory activity (A, B, middle panels) that 
was associated with a less invasive/metastatic phenotype (A, B, right panels). Means ± SD of three independent experiments run in triplicate are shown 
(*P < 0.05, ***P < 0.001). C). DU145 cells exposed for 4 days to BMP-2 (50-100 ng/ml) show significant reduction of soluble β-catenin that correlates 
with less active AKT, reduced cyclin D1 levels (D) and increased expression of E-cadherin (D), all indicative of a less metastatic phenotype. The exper-
iments were carried out independently two times and PC3 gave similar results. Protein expression, relative to controls set at 1, is shown.Benelli et al. Molecular Cancer 2010, 9:142
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One possible explanation for the contrasting results may
be related to the low dose used in humans compared to
those that were effective in animal studies or to the low
bioavailability of 4HPR at the prostate tissue level as doc-
umented in biopsies [34]. The elucidation of molecular
pathways activated by 4HPR are fundamental clues to
understand how this agent might be better used in a pre-
vention setting and current trials are underway to re-
examine both dose and schedule of 4HPR administration
as well as the target tissues of interest.
Our study was designed to investigate the early effects
of 4HPR on activated pathways, and regulated gene prod-
ucts, that control prostate cancer cell migration, invasion
and proliferation later on. We found that 4HPR inhibited
phosphorylated FAK, a protein tyrosine kinase localized
at the cell membrane that signals through the PI3K/AKT
pathway. Increasing levels of FAK in human prostate can-
cer correlate with greater metastatic potential [35]. FAK
overexpression appeared in PIN lesions, with a clear dis-
tribution of high staining in neoplastic cells, while normal
cells in the surrounding tissue did not show elevated
expression [36]. Furthermore, benign prostate hyperpla-
sia did not show a change in FAK expression compared to
normal tissue [36]. These observations support a role for
FAK in the pre-metastasis phenotype. We provide evi-
dence that the FAK-mediated decrease of AKT activity by
4HPR treatment, as well as AKT inactivation/activation
with Wortmannin or LY294002 and IGF-I or Myr.Akt,
respectively, tightly controls the chemotactic and meta-
static phenotype of androgen-independent prostate car-
cinoma cells and may also explain the already described
suppression of constitutive NF-kB activation, mediating
invasion and osteoclastogenesis, in human prostate can-
cer cells exposed to 4HPR [12,37]. Moreover, as both FAK
and AKT signaling controls prostate tumor angiogenesis
by up-regulating vascular endothelial growth factor
[22,38], our results showing reduction of VEGF release by
4HPR could be associated with FAK and AKT decreased
activity.
The Wnt signaling pathway and its key component β-
catenin play critical roles in embryonic development as
well as in human diseases, including various malignan-
cies. Accumulated evidence has demonstrated a signifi-
cant role for the Wnt pathway in the development and
progression of human prostate cancer. In the absence of a
Wnt signal, β-catenin is constitutively down-regulated by
a multicomponent phosphorylation destruction complex
containing active GSK3β and targeted for degradation by
the ubiquitin proteasome pathway. Stimulation of the
Wnt pathway results in increased levels of nuclear β-
catenin, which activates target genes (i.e cyclinD1) pro-
moting G1-S transition and cell cycling. High levels of
Wnt and β-catenin are associated with advanced, meta-
static, hormone-refractory prostate carcinoma [24].
Blockade of β-catenin signaling by chemopreventive
agents suppresses prostate carcinogenesis and metastasis
in TRAMP mice and decreased proliferation and inva-
siveness in DU145 cells, similar to that obtained with
siRNA directed against β-catenin [33]. Our data show
that both DU145 and PC3 cell lines have high basal levels
of soluble β-catenin indicative of an active Wnt signaling.
We cannot exclude that 4HPR treatment, besides
decreasing AKT phosphorylation, leads to β-catenin deg-
radation by affecting other pathways inducing GSK3β
phosphorylation such as Wnt- and ERK-mediated signal-
ing.
Retinoids and the synthetic derivative 4HPR regulate
gene expression through the RAR/RXR nuclear receptor
family (NR). Retinoid-activated RAR and RXR are potent
repressors of β-catenin signaling in retinoid-sensitive
cells [39-41] and retinoid-mediated repression of several
Wnt genes has been implicated as a required step in the
differentiation of neuronal cells [42]. These mechanisms
may further contribute to the effectiveness of 4HPR as a
chemopreventive agent in cancers with hyperactive Wnt
signaling. Moreover, as β-catenin has the ability to
enhance androgen receptor (AR) function in prostate
cancer [43], the obvious therapeutic goal to abrogate
potential oncogenic AR/β-catenin interactions can be
easily achieved through the chemopreventive properties
of 4HPR also in hormone responsive cells.
Prostate cancer has the ability to produce angiogenic
factors and several studies showed that an increased
microvessel density is associated with poorer prognosis.
We and others [4,12-16,44,45] have previously demon-
strated that one possible mechanism of the chemopre-
ventive activity of 4HPR is through inhibition of
angiogenesis and invasion, in part mediated by BMP-2
production [14]. In long-term experiments, prostate can-
cer cells exposed to BMP-2 concentrations attainable in
vitro (50-100 ng/ml) from endothelial cells exposed to 5
μM 4HPR, showed a slight but significant decreased pro-
liferation and reduced chemotactic and invasive activi-
ties. These effects again associate with decreased AKT
activity and lower levels of β-catenin and cyclin D1, indic-
ative of an interference with the β-catenin pathway, as
already described in intestinal tumorigenesis in mice and
humans [30,31]. Of note, BMP-2 treatment also induced
E-cadherin expression, indicative of a less metastatic phe-
notype. The role of BMPs in the formation of prostate
cancer metastasis to bone remains unknown as demon-
strated by the great number of published contrasting
results. BMP-2, 4, 6 and 7 have in fact been shown to both
induce and prevent bone metastasis [32,46-51]. These
contrasting results may be generated by the different
experimental approaches utilized, time of exposure and
concentrations of BMPs employed. We indeed obtained
enhanced migration and invasion only when the cellsBenelli et al. Molecular Cancer 2010, 9:142
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were exposed to BMP-2 during the 5 hours of the assay
(data not shown).
Conclusion
A large number of evidences point into the same direc-
tion: FAK, and its downstream signaling molecules AKT
and GSK-3β, β-catenin and its upstream and downstream
signaling molecules Wnt and cyclin D1, respectively, are
important players in both prostate tumor development
and metastasis. Simultaneous manipulation by the
chemopreventive 4HPR of a number of signaling path-
ways, both in cancer and endothelial cells, all involved in
the processes of tumor progression and metastasis for-
mation is likely to be more effective than manipulation of
single target molecules. Investigation of Wnt signaling
molecules and identification of synergisms between
4HPR and other candidate chemopreventive molecules
with complementary mechanisms of action may support
future assessment of this prototype cancer preventive
retinoid as an anti metastatic drug.
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